- Home
- PHM vs RVMD Comparison
PHM vs RVMD Comparison
Compare PHM & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHM | RVMD |
|---|---|---|
| Founded | 1950 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 19.2B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHM | RVMD |
|---|---|---|
| Price | $120.62 | $140.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | $136.23 | ★ $140.84 |
| AVG Volume (30 Days) | 1.8M | ★ 3.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.50 | $533.02 |
| P/E Ratio | $69.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $95.20 | $34.00 |
| 52 Week High | $144.50 | $155.70 |
Technical Indicators
Market Signals| Indicator | PHM | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.44 | 62.82 |
| Support Level | $113.93 | $93.39 |
| Resistance Level | $122.27 | $155.70 |
| Average True Range (ATR) | 3.71 | 7.53 |
| MACD | 0.22 | -0.07 |
| Stochastic Oscillator | 12.14 | 75.43 |
Price Performance
Historical ComparisonAbout PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.